Two mRNA vaccines (CV-9103 and CV-9104) based on four prostate-specific antigens (STEAP, PSCA, PSMA, and PSA), have showed good tolerability and favorable immune-activation in phase I/II clinical trials in prostate cancer patients (17). The gene discussed is KLK3; the disease is Familial prostate cancer.